Loading clinical trials...
Loading clinical trials...
Alzheimer's Disease (AD) affects tens of millions of people just in Europe. It is typically detected in its late stage when irreversible damage has already occurred, and current treatments are mostly conservative or palliative. Here we developed a device performing high-resolution multispectral imaging of the eye fundus to detect AD in its early stage. After clinical testing, the proposed device has a high potential to become a method for routine population screening, as it is non-invasive and affordable. The possibility of AD detection in an early stage is crucial for developing a new pharmaceutical treatment that would dramatically improve the lives of millions and save the expenses connected to lifelong healthcare assistance to people with AD in later stages.
Age
55 - No limit years
Sex
ALL
Healthy Volunteers
Yes
Santa Lucia Foundation
Rome, Italy, Italy
Start Date
May 1, 2023
Primary Completion Date
December 1, 2025
Completion Date
March 1, 2026
Last Updated
February 24, 2025
80
ESTIMATED participants
Fundoscopic Exam
DIAGNOSTIC_TEST
Lead Sponsor
I.R.C.C.S. Fondazione Santa Lucia
NCT04123314
NCT07178210
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions